作者
Robert K Naviaux, Brooke Curtis, Kefeng Li, Jane C Naviaux, A Taylor Bright, Gail E Reiner, Marissa Westerfield, Suzanne Goh, William A Alaynick, Lin Wang, Edmund V Capparelli, Cynthia Adams, Ji Sun, Sonia Jain, Feng He, Deyna A Arellano, Lisa E Mash, Leanne Chukoskie, Alan Lincoln, Jeanne Townsend
发表日期
2017/7
期刊
Annals of Clinical and Translational Neurology
卷号
4
期号
7
页码范围
491-505
简介
Objective
No drug is yet approved to treat the core symptoms of autism spectrum disorder (ASD). Low‐dose suramin was effective in the maternal immune activation and Fragile X mouse models of ASD. The Suramin Autism Treatment‐1 (SAT‐1) trial was a double‐blind, placebo‐controlled, translational pilot study to examine the safety and activity of low‐dose suramin in children with ASD.
Methods
Ten male subjects with ASD, ages 5–14 years, were matched by age, IQ, and autism severity into five pairs, then randomized to receive a single, intravenous infusion of suramin (20 mg/kg) or saline. The primary outcomes were ADOS‐2 comparison scores and Expressive One‐Word Picture Vocabulary Test (EOWPVT). Secondary outcomes were the aberrant behavior checklist, autism treatment evaluation checklist, repetitive behavior questionnaire, and clinical global impression questionnaire.
Results
Blood levels of …
学术搜索中的文章
RK Naviaux, B Curtis, K Li, JC Naviaux, AT Bright… - Annals of Clinical and Translational Neurology, 2017
